Samyr

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• ADHD [Insufficient Evidence]
• aging [Insufficient Evidence]
• alcoholic liver disease [Insufficient Evidence]
• Alzheimer disease [Insufficient Evidence]
• back pain [Insufficient Evidence]
• cholestasis [Possibly Effective]
• chronic fatigue syndrome [Insufficient Evidence]
• depression [Possibly Effective]
• epilepsy [Insufficient Evidence]
• fatigue, cancer-related [Insufficient Evidence]
• fibromyalgia [Insufficient Evidence]
• Gilbert syndrome [Insufficient Evidence]
• hepatic cirrhosis [Insufficient Evidence]
• hepatitis C [Insufficient Evidence]
• lead toxicity [Insufficient Evidence]
• menopausal symptoms [Insufficient Evidence]
• migraine [Insufficient Evidence]
• multiple sclerosis [Insufficient Evidence]
• osteoarthritis [Likely Effective]
• premenstrual syndrome [Insufficient Evidence]
• schizophrenia [Insufficient Evidence]
• sexual dysfunction, antidepressant-induced [Insufficient Evidence]
• smoking cessation [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

ADHD

[Insufficient Evidence]

Dose: 400-800 mg PO tid; Info: given 30-60min before meals or 120min after meals

alcoholic liver disease

[Insufficient Evidence]

Dose: 400 mg PO tid; Info: given 30-60min before meals or 120min after meals

cholestasis

[Possibly Effective (PO route)]

Dose: 1000-1600 mg/day PO divided qd-bid; Info: given 30-60min before meals or 120min after meals

[Possibly Effective (IV route)]

Dose: 500 mg IV bid x2wk, then 500 mg PO bid; Alt: 800 mg IV qd x2-3wk, then 1600 mg PO qd

depression

[Possibly Effective]

Dose: 1600-3200 mg PO qd; Info: used w/ conventional tx; given 30-60min before meal or 120min after meal

fatigue, cancer-related

[Insufficient Evidence]

Dose: 400 mg PO bid; Info: given 30-60min before meals or 120min after meals

fibromyalgia

[Insufficient Evidence (PO route)]

Dose: 400 mg PO bid; Info: given 30-60min before meals or 120min after meals

[Insufficient Evidence (IM route)]

Dose: 200 mg IM qd; Alt: 200 mg IM qd plus 200 mg PO bid given 30-60min before meals or 120min after meals

[Insufficient Evidence (IV route)]

Dose: 400 mg IV qd

Gilbert syndrome

[Insufficient Evidence (PO route)]

Dose: 1200 mg PO qd; Info: given 30-60min before meal or 120min after meal

[Insufficient Evidence (IV route)]

Dose: 200-800 mg IV qd

hepatic cirrhosis

[Insufficient Evidence (PO route)]

Dose: 600 mg PO qd; Info: given 30-60min before meal or 120min after meal

[Insufficient Evidence (IV route)]

Dose: 600 mg IV bid x3 days, then 400 mg PO tid given 30-60min before meals or 120min after meals; Alt: 500-800 mg/day IV divided qd-bid; 15 mg IV qid

hepatitis C

[Insufficient Evidence]

Dose: 1600 mg PO qd; Alt: 400 mg PO tid; Info: used w/ conventional tx; given 30-60min before meals or 120min after meals

osteoarthritis

[Likely Effective (PO route)]

Dose: 600-1200 mg/day PO divided qd-tid; Alt: 400 mg PO tid x1wk, then 400 mg PO bid x1wk, then 400 mg PO qd; 600 mg PO qd x2wk, then 400 mg PO qd; Info: given 30-60min before meals or 120min after meals

[Likely Effective (IV route)]

Dose: 400 mg IV qd x5 days, then 200 mg PO tid given 30-60min before meals or 120min after meals

schizophrenia

[Insufficient Evidence]

Dose: 400 mg PO bid; Start: 200 mg PO bid x1wk; Info: given 30-60min before meals or 120min after meals

sexual dysfunction, antidepressant-induced

[Insufficient Evidence]

Dose: 800 mg PO bid; Start: 400 mg PO bid x2wk; Info: given 30-60min before meals or 120min after meals